CSTL CEO Maetzold nets insider sales, option exercises
CASTLE BIOSCIENCES INC President and CEO Derek J. Maetzold reported a series of insider trades in May 2026 involving company common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CASTLE BIOSCIENCES INC President and CEO Derek J. Maetzold reported a series of insider trades in May 2026 involving company common stock. Across several family trusts and a personal account, entities associated with him sold a net 4,172 shares in open-market transactions at prices around $20 per share.
On the same dates, he exercised stock options to acquire 550 shares at an exercise price of $2.39 per share, increasing his direct common stock holdings. Following these transactions, one direct holding account shows 21,479 shares, while certain family trusts continue to hold tens of thousands of shares. The filing notes that these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 420 | $0.00 | $0.00 |
| Exercise | Common Stock | 420 | $2.39 | $1K |
| Sale | Common Stock | 420 | $20.196 | $8K |
| Sale | Common Stock | 1,035 | $20.196 | $21K |
| Sale | Common Stock | 880 | $20.196 | $18K |
| Sale | Common Stock | 212 | $20.196 | $4K |
| Sale | Common Stock | 212 | $20.196 | $4K |
| Sale | Common Stock | 212 | $20.196 | $4K |
| Sale | Common Stock | 212 | $20.196 | $4K |
| Exercise | Stock option (right to buy) | 130 | $0.00 | $0.00 |
| Exercise | Common Stock | 130 | $2.39 | $310.70 |
| Sale | Common Stock | 130 | $20.002 | $3K |
| Sale | Common Stock | 322 | $20.002 | $6K |
| Sale | Common Stock | 273 | $20.002 | $5K |
| Sale | Common Stock | 66 | $20.002 | $1K |
| Sale | Common Stock | 66 | $20.002 | $1K |
| Sale | Common Stock | 66 | $20.002 | $1K |
| Sale | Common Stock | 66 | $20.002 | $1K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (13)
- F1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $20.000 to $20.010, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
- F4. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
- F5. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
- F6. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F7. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F8. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F9. This transaction was executed in multiple trades at prices ranging from $20.005 to $20.350, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F10. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary.
- F11. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
- F12. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
- F13. The shares subject to the option are fully vested.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
Grantor Retained Annuity Trust financial
Stock option (right to buy) financial
weighted-average sale price financial
irrevocable trust financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did CSTL CEO Derek Maetzold report in this Form 4?
Did Derek Maetzold exercise any Castle Biosciences stock options in this filing?
Which trusts linked to Derek Maetzold were involved in the CSTL trades?
AI-generated analysis. How Rhea-AI works. Not financial advice.